Insider Selling: Xencor (NASDAQ:XNCR) CEO Sells 6,606 Shares of Stock

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil Dahiyat sold 6,606 shares of Xencor stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $11.02, for a total transaction of $72,798.12. Following the completion of the transaction, the chief executive officer directly owned 546,316 shares of the company’s stock, valued at $6,020,402.32. This trade represents a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Xencor Stock Performance

XNCR traded up $0.55 on Monday, hitting $11.87. 835,908 shares of the company’s stock were exchanged, compared to its average volume of 711,120. The firm has a market cap of $870.55 million, a PE ratio of -9.57 and a beta of 0.95. Xencor, Inc. has a twelve month low of $6.92 and a twelve month high of $18.69. The stock has a fifty day moving average of $12.79 and a two-hundred day moving average of $13.00. The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.55. The company had revenue of $28.24 million during the quarter, compared to the consensus estimate of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.Xencor’s quarterly revenue was down 46.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.62) earnings per share. On average, research analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on XNCR shares. Truist Financial started coverage on Xencor in a research report on Monday, November 24th. They issued a “buy” rating and a $29.00 target price on the stock. Barclays upped their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Finally, Wall Street Zen lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in XNCR. Hantz Financial Services Inc. boosted its position in shares of Xencor by 209.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 2,156 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 1,449 shares in the last quarter. Farther Finance Advisors LLC acquired a new stake in Xencor during the third quarter valued at approximately $44,000. Tower Research Capital LLC TRC lifted its holdings in shares of Xencor by 118.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 3,018 shares during the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Xencor by 114.3% in the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 2,105 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.